FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:737-738 August 17, 2006 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Chung, R. T. PubMed Citation

To the Editor: The discovery of a V617F mutation in the Janus kinase 2 (JAK2) gene was a seminal advance in our understanding of the chronic myeloproliferative disorders (MPDs). Ostensibly, the recent Case Record by Chung et al. (May 18 issue)¹ was chosen to showcase the expression of this mutation in defining the cause of hepatic-vein thrombosis. However, although the expression of the V617F mutation identifies the presence of an MPD, it does not define the limits of the phenotype, and the absence of the mutation does not rule out an MPD.

The discussants focused on borderline thrombocytosis . . . [Full Text of this Article]

This article has been cited by other articles:

• Spivak, J. L., Silver, R. T. (2008). The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112: 231-239 [Full Text]  
• Kiladjian, J.-J., Cervantes, F., Leebeek, F. W. G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.-C., Murad, S. D., Raffa, S., Janssen, H. L. A., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P., Valla, D. C. (2008). The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111: 4922-4929 [Abstract] [Full Text]